期刊文献+

HPLC法测定复方氨氯地平缬沙坦片有关物质 被引量:6

Determination of Related Substances in Compound Amlodipine and Valsartan Tablets by HPLC
下载PDF
导出
摘要 目的:建立测定复方氨氯地平缬沙坦片有关物质的HPLC方法。方法:用Agilent Extend C_(18)(250mm×4.6mm,5μm)色谱柱,以0.01mol·L^(-1)磷酸二氢钾溶液(pH 3.5)-(甲醇:乙腈=10:40)为流动相,梯度洗脱,流速1.0ml·min^(-1),柱温40℃,检测波长250nm,进样量20μl。结果:有关物质各杂质峰与主峰之间的分离良好,且已知单个杂质分离良好。结论:该方法准确可靠,专属性强,可用于复方氨氯地平缬沙坦片有关物质测定。 Objective:To establish an HPLC method for the determination of related substances in compound amlodipine and valsartan tablets.Method:Agilent Extend C18column(250 mm×4.6 mm,5μm)was used with 0.01 mol·L^-1KH2PO4 buffer(pH 3.5)-methanol:acetronitrile of 10:40 as the mobile phase with gradient elution at a flow rate of 1.0 ml·min^-1.The column temperature was 40℃and the detection wavelength was 250 nm.Injection volume was 20μl.Result:Amlodipine,valsartan and their related substances could be well separated.Conclusion:This method is accurate,specific and sensitive,and can be used for the determination of related substances in compound amlodipine and valsartan tablets.
出处 《中国药师》 CAS 2011年第8期1142-1144,共3页 China Pharmacist
关键词 复方氨氯地平缬沙坦片 有关物质 高效液相色谱法 Compound amlodipine and valsartan tablets Related substances HPLC
  • 相关文献

参考文献5

  • 1王玉红,白秋江,赵军,胡跃民.氨氯地平缬沙坦复合片的临床应用[J].中国药师,2009,12(12):1818-1820. 被引量:3
  • 2USP[S].32th ed.2009.467-470.1136-1141.
  • 3Mustafa C,Mustfa SK,Sacide A,et al.Validated HPLC method devel opment:The simultaneous analysis of amLodipine and valsartan in samples for liver perfusion studies[J].Hacettepe University Journal of the Faculty of Pharmacy,2008,28(1):15-17.
  • 4Shehal BP,Bharat GC,Munish KB,et al.Stability indicating RP HPLC method for simultaneous determination of valsartan and amLo dipine from their combination drug product[J].Chem Tech,2009,1 (4):1257-1260.
  • 5中国药典[S].2010年版.二部.附录ⅨJ.

二级参考文献11

  • 1Abemethy DR, Pharmacokinetics and pharmacodynamics of amlodipine [ J ]. Cardiology, 1992, 80 ( Suppl 1 ) : s31 -s36.
  • 2Flesch G, Muller P,Lloyd P, Absolute bioavailability and pharmacokinetics of valsartan, an angiotensln II receptor antagonist, in man [ J ]. Xenobiotica, 1997,27( 1 ) :59-71.
  • 3Preston RA, Chung M, Gaffney M, et al. Comparative pharmacokinetics and pbarmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus[ J]. J C Pharnu~o, 2001,41 (11 ) :1215-1224.
  • 4Julius S, Weber MA, Kjeldsen SE, et al. The Valsarten Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy [ J ]. Hypertension, 2006,48 ( 3 ) : 385 -391.
  • 5Smith TR,Philipp T,Vaisse B,et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies [J].Clin Hypertension, 2007,9(5) :355-364.
  • 6Philipp T, Smith TR; Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the etficaey and tolerability of amlodipine and valsartan in combination and as monmbexapy in adult patients with mild to moderate essential hypertension[ J ]. Clin Tnera-peutics ,2007,29(4) :563-580.
  • 7Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressurelowering efficacy of the combination of anflodipine plus valsartan compared with lisinopril plus hydmchlomthiazide in adult patients with stage 2 hypertension [ J ]. Clinical therapeutics,2007,29 (2) :279 -289.
  • 8Fogari R, Zoppi A, Derosa G,et al. Effect of Valsartan addition to amlodipine on ankle oederaa and subcutaneous tissue pressure in hypertensive patients[ J]. J Human Hypertension,2007,21 ( 3 ) :220-224.
  • 9Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled tri- M to evaluate the efficacy, safety, and pharmacodynamic interaction of coati- ministered amJodipine and atorvaslatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial[ J]. J Clin Pharmacol, 2007, 47 (12) : 1555-1569.
  • 10Fogad R, Zoppi A. Effect of indomethacln on the antihypertenslve efficaey of valsartan and lisinopril : a muhicentre study [ J ]. J Hypertens, 2002,20 ( 5 ) : 1007-1014.

共引文献346

同被引文献29

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部